β-Cell function in mild type 2 diabetic patients: Effects of 6-month glucose lowering with nateglinide

Diabetes Care

Volumn 28, Issue 5, 2005, Pages 1132-1138

  Mari, Andrea ^a   Gastaldelli, Amalia ^b,c   Foley, James E ^d   Pratley, Richard E ^d   Ferrannini, Ele ^b,c  

^a CNR   (Italy)

^b UNIVERSITY OF PISA   (Italy)

^c INSTITUTE OF CLINICAL PHYSIOLOGY   (Italy)

^d NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; GLUCOSE; NATEGLINIDE; PLACEBO;

ADULT; AGED; ARTICLE; CELL FUNCTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DIET RESTRICTION; DIET THERAPY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG MEGADOSE; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN RELEASE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; METABOLISM; MULTIPLE REGRESSION; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; POSTPRANDIAL STATE; RANDOMIZED CONTROLLED TRIAL; STANDARDIZATION;

AGED; BLOOD GLUCOSE; CYCLOHEXANES; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; ISLETS OF LANGERHANS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; PHENYLALANINE; PLACEBOS; SEVERITY OF ILLNESS INDEX;

EID: 18144419321     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.28.5.1132     Document Type: Article

References (15)

1. Kahn SE, Porte D Jr: The pathophysiology of type II (noninsulin- dependent) diabetes mellitus: implications for treatment. In Ellenberg and Rifkin's Diabetes Mellitus: Theory and Practice. 5th ed. Porte D Jr., Sherwin RS, Eds. Stamford, CT, Appletone and Lange, 1997, p. 487-512
2. Kahn SE: The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of type 2 diabetes. Diabetologia 46:3-19, 2003
3. Ferrannini E: Insulin resistance versus insulin deficiency in non-insulin-dependent diabetes mellitus: problems and prospects. Endocr Rev 19:477-490, 1998
4. Weyer C, Bogardus C, Mott DM, Pratley RE: The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest 104:787-794, 1999
5. Mari A, Schmitz O, Gastaldelli A, Oestergaard T, Nyholm B, Ferrannini E: Meal and oral glucose tests for the assessment of beta-cell function: modeling analysis in normal subjects. Am J Physiol Endocrinol Metab E1159-E1166, 2002
6. Mari A, Tura A, Gastaldelli A, Ferrannini E: Assessing insulin secretion by modeling in multiple-meal tests: role of potentiation. Diabetes 51 (Suppl. 1):S221-S226, 2002
7. Ferrannini E, Gastaldelli A, Miyazaki Y, Matsuda M, Pettiti M, Natali A, Mari A, DeFronzo R: Predominant role of reduced beta-cell sensitivity to glucose over insulin resistance in impaired glucose tolerance. Diabetologia 46:1211-1219, 2003
8. Ferrannini E, Gastaldelli A, Miyazaki Y, Matsuda M, Mari A, Defronzo RA: Beta-cell function in subjects spanning the range from normal glucose tolerance to overt diabetes: a new analysis. J Clin Endocrinol Metab 90:493-500, 2005
9. Saloranta C, Hershon K, Ball M, Dickinson S, Holmes D: Efficacy and safety of nateglinide in type 2 diabetic patients with modest fasting hyperglycemia. J Clin Endocrinol Metab 87:4171-4176, 2002
10. Hu S, Boettcher BR, Dunning BE: The mechanisms underlying the unique pharmacodynamics of nateglinide. Diabetologia 46 (Suppl 1):M37-M43, 2003
11. Ferrannini E, Mari A: Beta cell function and its relation to insulin action in man: a critical appraisal. Diabetologia 47:943-956, 2004
12. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC: Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412-419, 1985
13. Mari A, Pacini G, Murphy E, Ludvik B, Nolan JJ: A model-based method for assessing insulin sensitivity from the oral glucose tolerance test. Diabetes Care 24:539-548, 2001
14. Bruttomesso D, Pianta A, Mari A, Valerio A, Marescotti MC, Avogaro A, Tiengo A, DelPrato S: Restoration of early rise in plasma insulin levels improves the glucose tolerance of type 2 diabetic patients. Diabetes 48:99-105, 1999
15. Hu S, Wang S, Fanelli B, Bell PA, Dunning BE, Geisse S, Schmitz R, Boettcher BR: Pancreatic beta-cell K(ATP) channel activity and membrane-binding studies with nateglinide: a comparison with sulfonylureas and repaglinide. J Pharmacol Exp Ther 293:444-452, 2000